|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Plant platform for therapeutic monoclonal antibody productionстатья
- Авторы: Dorokhov Y.L., Sheshukova E.V., Komarova T.V.
- Сборник: Plant Biotechnology: Progress in Genomic Era" (by S.M. Paul Khurana & R.K Gaur)
- Глава в коллективной монографии
- Год издания: 2019
- Место издания: Springer Verlag, Germany Berlin
- Аннотация: Plant cells have protein synthesis and post-translational modification (glycosylation and phosphorylation) mechanisms similar to those of animal cells therefore the development of biotechnology allows considering plants as factories for therapeutic proteins, including therapeutic monoclonal antibodies (TMAs). The plant monoclonal antibody production platform has attracted researchers’ attention due to its flexibility, speed, scalability, low production costs, and absence of a risk of contamination by pathogens of animal origin. Modern methods for the production of therapeutic proteins are based on stably transformed transgenic plants and the transient expression of foreign genes. This chapter considers modern methods for obtaining TMAs produced in plants (P-TMA), features of the carbohydrate composition and methods for humanising the carbohydrate profile of P-TMAs. Examples of P-TMAs that have successfully passed preclinical trials and have a perspective in clinical use are given. The prospects of P-TMAs are determined by the economic benefits and speed of production, which are especially important for individualised cancer therapy, as well as cases of bioterrorism and pandemics.
- Добавил в систему: Дорохов Юрий Леонидович